A team of researchers in China has developed a handheld cancer detection device that may significantly speed up early cancer screening. The portable tool is designed to identify cancer-related biomarkers from a single drop of blood in around 15 minutes, potentially making diagnostics faster, cheaper, and more accessible in the future.
A portable breakthrough in cancer screening
Scientists from Westlake University in China have created a pocket-sized device that can detect early-stage cancer biomarkers using a minimally invasive blood sample. In clinical trials, the system reportedly showed up to 94.9% accuracy in identifying early lung cancer indicators.
Researchers say the innovation could help shift cancer diagnostics out of specialised laboratories and into clinics, remote healthcare settings, and possibly even home monitoring in the future.
How the handheld device works
Unlike traditional laboratory-based cancer tests that rely on large and expensive equipment, the new system uses a compact optical sensing method.
The device is built around a light-based technique called Q-modulated refractometric sensing, which detects tiny biological particles known as small extracellular vesicles (sEVs). These particles can serve as early warning signals for cancer development.
The system consists of just three main components: a 3D sensing chip, an LED light source, and a photodetector. Researchers also used nanophotonic structures and engineered metamaterials to enhance sensitivity while keeping the device small and portable.
What early trials revealed
In tests involving more than 170 blood serum samples from lung cancer patients, the device demonstrated:
- Up to 94.9% accuracy in early lung cancer detection
- Around 92.1% accuracy for post-surgical monitoring
- Nearly 10,000 times higher sensitivity compared to conventional ELISA testing methods
- Detection time of approximately 15 minutes per sample
The results suggest the system could significantly reduce turnaround times compared to standard diagnostic procedures.
Why scientists are excited — and cautious
The development is part of a broader global push toward “liquid biopsy” technologies, which aim to detect cancer through blood-based markers rather than invasive tissue samples.
Experts note that such portable systems could be particularly valuable in rural or resource-limited regions where access to advanced cancer screening is restricted.
However, researchers also caution that the technology is still in early stages. Larger clinical trials, regulatory approvals, and further validation are needed before it can be used widely in hospitals or at home. Accuracy alone is not sufficient; measures like sensitivity and false-negative rates will be critical in determining real-world effectiveness.
The road ahead
While still experimental, the handheld device reflects a growing trend in medical innovation: making diagnostics smaller, faster, and more accessible. If future trials confirm its performance, it could mark a major step forward in early cancer detection and monitoring.